Teva's Layoffs Signal Deeper Fault Lines In The Pharmaceutical Business Model

Teva's Layoffs Signal Deeper Fault Lines In The Pharmaceutical Business Model
Forbes contributors provide expert analyses. Teva's layoffs reflect challenges in the pharmaceutical sector, where generics struggle against branded drugs due to market structures favoring profits. The need to reform incentives, curb PBM influence, and prioritize value and competition is crucial for sustainable drug costs and innovation.